Jim Cramer, portfolio manager of TheStreet’s Action Alerts PLUS and host of CNBC’s ‘Mad Money’ discussed pipeline companies while answering viewers’ questions Friday. Cramer said he bought some shares of Energy Transfer Partners (ETP) on Thursday for the charitable trust. Several viewers asked about Kinder Morgan (KMI), which TheStreet has reported on extensively this week. Cramer said it’s a fluid situation, and advised investors to read articles about the company written by Real Money writers Dan Dicker and Carleton English. Cramer was also asked whether Chevron (CVX) and Exxon Mobil (XOM) will bounce, and he responded there’s a big short position in oil, and there are other stocks outside of the oil patch to focus on. One of the stocks he does like is Medtronic (MDT), saying the company is doing a lot of things right. He is also a fan of Allergan (AGN). In the food group, Cramer said he prefers Tyson (TSN) to Cal-Maine (CALM). Another viewer asked about Avon (AVP), after reports that the company is in talks to sell its North American business. Cramer responded, ‘that money’s not going to you shareholders, be very careful.’ Send your questions to Jim Cramer on Facebook and Twitter to @JimCramer, using #CramerQ.
More from Video
Amid the Selling, Here's the Big Question Now
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.